Tomohiro Fujiwara1, Miyuki Fujiwara2, Kunihiko Numoto1, Koichi Ogura1, Akihiko Yoshida3, Tsukasa Yonemoto4, Shigenobu Suzuki2, Akira Kawai5. 1. Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo. 2. Division of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo. 3. Division of Pathology, National Cancer Center Hospital, Tokyo. 4. Division of Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan. 5. Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo akawai@ncc.go.jp.
Abstract
OBJECTIVE: Second primary malignancies have become the leading cause of death in retinoblastoma survivors. Although osteosarcoma is the most common second malignancy, little is known about its clinical and therapeutic features. METHODS: We retrospectively reviewed a database of patients with retinoblastoma and osteosarcoma occurring as a second malignancy between 1964 and 2010 at the National Cancer Center Hospital of Japan. RESULTS: Among 857 patients with retinoblastoma registered in the database, 10 (1.1%) developed osteosarcoma as a second malignancy. The median age at the onset of retinoblastoma was 3 months, being bilateral in nine patients and unilateral in one. Systemic chemoreduction was performed in three patients and intra-arterial chemotherapy in six; all patients received external beam radiotherapy. The median age at the onset of second primary osteosarcoma was 11.2 years; four were radiation-related and six were located in an extremity. Among five patients treated at our institute, four patients with tumors on an extremity were treated by wide resection with neoadjuvant and adjuvant chemotherapy. Three of these four patients (75%) were good responders to high-dose methotrexate-based multi-agent chemotherapy and survived with no evidence of disease (median follow-up period, 17.3 years). One patient whose temporal bone was affected underwent radiotherapy with chemotherapy but died after local recurrence. CONCLUSIONS: The clinical outcomes of second primary osteosarcoma in an extremity occurring in retinoblastoma survivors may be more favorable than those of conventional osteosarcoma. Early diagnosis of radiation-related osteosarcoma arising in the craniofacial region should be made at a stage where complete resection is possible.
OBJECTIVE: Second primary malignancies have become the leading cause of death in retinoblastoma survivors. Although osteosarcoma is the most common second malignancy, little is known about its clinical and therapeutic features. METHODS: We retrospectively reviewed a database of patients with retinoblastoma and osteosarcoma occurring as a second malignancy between 1964 and 2010 at the National Cancer Center Hospital of Japan. RESULTS: Among 857 patients with retinoblastoma registered in the database, 10 (1.1%) developed osteosarcoma as a second malignancy. The median age at the onset of retinoblastoma was 3 months, being bilateral in nine patients and unilateral in one. Systemic chemoreduction was performed in three patients and intra-arterial chemotherapy in six; all patients received external beam radiotherapy. The median age at the onset of second primary osteosarcoma was 11.2 years; four were radiation-related and six were located in an extremity. Among five patients treated at our institute, four patients with tumors on an extremity were treated by wide resection with neoadjuvant and adjuvant chemotherapy. Three of these four patients (75%) were good responders to high-dose methotrexate-based multi-agent chemotherapy and survived with no evidence of disease (median follow-up period, 17.3 years). One patient whose temporal bone was affected underwent radiotherapy with chemotherapy but died after local recurrence. CONCLUSIONS: The clinical outcomes of second primary osteosarcoma in an extremity occurring in retinoblastoma survivors may be more favorable than those of conventional osteosarcoma. Early diagnosis of radiation-related osteosarcoma arising in the craniofacial region should be made at a stage where complete resection is possible.
Authors: Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson Journal: Ophthalmology Date: 2020-05-15 Impact factor: 12.079
Authors: Danielle Novetsky Friedman; Meier Hsu; Chaya S Moskowitz; Jasmine H Francis; Eric Lis; Megan Harlan Fleischut; Kevin C Oeffinger; Michael Walsh; Emily S Tonorezos; Charles A Sklar; David H Abramson; Ira J Dunkel Journal: Pediatr Blood Cancer Date: 2020-05-09 Impact factor: 3.167
Authors: Kelly M Makielski; Lauren J Mills; Aaron L Sarver; Michael S Henson; Logan G Spector; Shruthi Naik; Jaime F Modiano Journal: Vet Sci Date: 2019-05-25
Authors: Ruth A Kleinerman; Sara J Schonfeld; Byron S Sigel; Jeannette R Wong-Siegel; Ethel S Gilbert; David H Abramson; Johanna M Seddon; Margaret A Tucker; Lindsay M Morton Journal: J Clin Oncol Date: 2019-10-17 Impact factor: 44.544